NCT03486314View on ClinicalTrials.gov

A Study to Evaluate the Effects of Rifampin on Pharmacokinetics (PK) of Pevonedistat in Participants With Advanced Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

August 13, 2018

Primary Completion Date

May 10, 2019

Study Completion Date

February 28, 2021

Conditions
Advanced Solid Neoplasm
Interventions
DRUG

Pevonedistat

Pevonedistat intravenous infusion.

DRUG

Rifampin

Rifampin capsules.

DRUG

Docetaxel

Docetaxel intravenous infusion.

DRUG

Carboplatin

Carboplatin intravenous infusion.

DRUG

Paclitaxel

Paclitaxel intravenous infusion.

Trial Locations (4)

29605

Greenville Health System - Institute for Translational Oncology Research, Greenville

30308

Emory University, Atlanta

60611

Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago

48201-2013

Barbara Ann Karmanos Cancer Institute, Detroit

Sponsors
All Listed Sponsors
lead

Millennium Pharmaceuticals, Inc.

INDUSTRY

NCT03486314 - A Study to Evaluate the Effects of Rifampin on Pharmacokinetics (PK) of Pevonedistat in Participants With Advanced Solid Tumors | Biotech Hunter | Biotech Hunter